For the study of malignant glioma, we have previously characterized a highly tumorigenic murine astrocytoma, SMA-560, which arose spontaneously in an inbred, immunocompetent VM/Dk mouse. Using this cell line as a model of murine glioma, we performed DNA microarray analysis of autologous normal murine astroctyes (NMA) and SMA-560 tumor cells grown in monolayer culture or intracranially in syngeneic immunocompetent or immunocompromised hosts in order to determine whether tumors grown in vitro recreate the complex genetic regulation that occurs in vivo. Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations.
Introduction
Despite the negligible incidence of metastasis, aggressive surgery and the application of novel treatments, malignant gliomas remain one of the most lethal forms of cancer (Wheeler et al., 2004) . This is due in large part to malignant brain tumors being relatively resistant to all forms of conventional or standardized therapy (Pulkkanen and YlaHerttuala, 2005) . Recent studies aimed at developing anticancer agents for glioma have begun to focus more on drugs that target specific molecules or processes selectively involved in glioma growth, survival and progression, rather than general cytotoxic agents (Ochiai et al., 2004; Sampson et al., 2000 Sampson et al., , 2005 . In general, the advantages of targeted therapy include decreased healthy tissue toxicity and the availability of molecular markers that serve as indicators of drug action, as well as improved patient morbidity and mortality.
Yet, despite best efforts, targeted therapy for malignant glioma has not been universally successful. This lack of success can be attributed to a number of critical factors, including well-documented tumor cell heterogeneity (Liang et al., 2005; Nutt et al., 2003) , antigen modulation (Cavenee, 2002; Louis, 2005) and the existence of multiple, redundant survival pathways (Heimberger et al., 2002; Learn et al., 2004) . Thus, it would appear that further development of target-based approaches to treating solid tumors such as malignant glioma requires a better understanding of the underlying biology that determines the expression of potential targets and their resistance (Mellinghoff et al., 2005 
